← Back to all trials
Not Yet Recruiting
NCT07632898
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Conditions: Pulmonary Arterial Hypertension (PAH)
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 484
Sponsor: Inhibikase Therapeutics
Summary
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
Eligibility Criteria
Inclusion Criteria:
* Capable of giving signed informed consent.
* Participants who have completed Study IKT-001-201 or any other Phase 2 or 3 controlled clinical study with IKT-001.
Exclusion Criteria:
* Any of the following clinical laboratory values at screening:
* ALT or AST levels \>3× the ULN
* Bilirubin levels \>2× the ULN
* ANC \
Source: ClinicalTrials.gov (NCT07632898). StuddyBuddy aggregates publicly available trial information.
